SG11202013062VA - Sulfonimidamide compounds as inhibitors of interleukin-1 activity - Google Patents
Sulfonimidamide compounds as inhibitors of interleukin-1 activityInfo
- Publication number
- SG11202013062VA SG11202013062VA SG11202013062VA SG11202013062VA SG11202013062VA SG 11202013062V A SG11202013062V A SG 11202013062VA SG 11202013062V A SG11202013062V A SG 11202013062VA SG 11202013062V A SG11202013062V A SG 11202013062VA SG 11202013062V A SG11202013062V A SG 11202013062VA
- Authority
- SG
- Singapore
- Prior art keywords
- interleukin
- inhibitors
- activity
- sulfonimidamide
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701313P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042711 WO2020018975A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202013062VA true SG11202013062VA (en) | 2021-02-25 |
Family
ID=67659954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013062VA SG11202013062VA (en) | 2018-07-20 | 2019-07-19 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210253596A1 (en) |
| EP (1) | EP3823974A1 (en) |
| JP (1) | JP7320595B2 (en) |
| KR (1) | KR20210034596A (en) |
| CN (1) | CN112513048A (en) |
| AR (1) | AR115822A1 (en) |
| AU (1) | AU2019306658A1 (en) |
| BR (1) | BR112021001044A2 (en) |
| CA (1) | CA3105521A1 (en) |
| CL (1) | CL2021000153A1 (en) |
| CO (1) | CO2021001530A2 (en) |
| CR (1) | CR20210022A (en) |
| IL (1) | IL279256A (en) |
| MA (1) | MA53172A (en) |
| MX (1) | MX2021000780A (en) |
| PE (1) | PE20211811A1 (en) |
| PH (1) | PH12021500005A1 (en) |
| SG (1) | SG11202013062VA (en) |
| TW (1) | TWI825134B (en) |
| WO (1) | WO2020018975A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018210525B2 (en) | 2017-01-23 | 2022-06-02 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| CN112437683A (en) | 2018-07-20 | 2021-03-02 | 豪夫迈·罗氏有限公司 | Sulfonylurea compounds useful as inhibitors of interleukin-1 activity |
| EP3880659B1 (en) * | 2018-11-16 | 2024-01-03 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| CN113329998A (en) * | 2019-01-23 | 2021-08-31 | 诺华股份有限公司 | Sulfonimidyl amide compounds and compositions for treating conditions associated with NLRP activity |
| CN114008030A (en) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | Fused 1, 2-thiazoles and 1, 2-thiazines as NLRP3 modulators |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| BR112022009209A2 (en) | 2019-11-12 | 2022-07-26 | Chengdu Baiyu Pharmaceutical Co Ltd | AMIGO DERIVATIVE AND METHOD OF PREPARATION AND USE IN MEDICINE |
| EP4093509A1 (en) * | 2020-01-22 | 2022-11-30 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as nlrp3 modulators |
| EP4121059A4 (en) * | 2020-03-16 | 2023-12-13 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| MX2022012897A (en) | 2020-04-15 | 2022-11-14 | Janssen Pharmaceutica Nv | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway. |
| JP2023521242A (en) | 2020-04-15 | 2023-05-23 | ヤンセン ファーマシューティカ エヌ．ベー． | Pyrrolo[1,2-d][1,2,4]triazin-2-yl-acetamide as an inhibitor of the NLRP3 inflammasome pathway |
| KR20230005252A (en) | 2020-04-23 | 2023-01-09 | 얀센 파마슈티카 엔.브이. | Tricyclic compounds as inhibitors of NLRP3 |
| JP2023523756A (en) | 2020-04-30 | 2023-06-07 | ヤンセン ファーマシューティカ エヌ．ベー． | Novel triazinoindole compounds |
| AU2021279305A1 (en) | 2020-05-28 | 2023-02-09 | Janssen Pharmaceutica Nv | Compounds |
| WO2021255279A1 (en) | 2020-06-19 | 2021-12-23 | Ac Immune Sa | D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| WO2022063896A1 (en) | 2020-09-24 | 2022-03-31 | Janssen Pharmaceutica Nv | New compounds |
| CN114539256B (en) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | Tricyclic compounds and medical uses thereof |
| MX2023010310A (en) | 2021-03-04 | 2023-09-12 | Janssen Pharmaceutica Nv | 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3. |
| JP2024508010A (en) | 2021-03-04 | 2024-02-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 4-amino-6-oxo-pyridazine derivatives that modulate NLRP3 |
| WO2022229315A1 (en) | 2021-04-29 | 2022-11-03 | Janssen Pharmaceutica Nv | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| TWI815439B (en) * | 2021-05-10 | 2023-09-11 | 大陸商成都百裕製藥股份有限公司 | Amide derivatives and applications thereof |
| WO2022237782A1 (en) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | Amide derivative and application thereof |
| WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
| TW202321262A (en) * | 2021-07-19 | 2023-06-01 | 美商建南德克公司 | Sulfonimidamde compounds and uses thereof |
| WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| WO2024010772A1 (en) * | 2022-07-06 | 2024-01-11 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
| WO2024064245A1 (en) | 2022-09-23 | 2024-03-28 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2975192A1 (en) | 2015-02-16 | 2016-08-25 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| AU2018210525B2 (en) | 2017-01-23 | 2022-06-02 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| MX2020000911A (en) * | 2017-07-24 | 2020-09-10 | Novartis Ag Star | Compounds and compositions for treating conditions associated with nlrp activity. |
| US11623922B2 (en) * | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
-
2019
- 2019-07-19 EP EP19753515.6A patent/EP3823974A1/en active Pending
- 2019-07-19 AU AU2019306658A patent/AU2019306658A1/en active Pending
- 2019-07-19 CR CR20210022A patent/CR20210022A/en unknown
- 2019-07-19 SG SG11202013062VA patent/SG11202013062VA/en unknown
- 2019-07-19 PE PE2021000082A patent/PE20211811A1/en unknown
- 2019-07-19 WO PCT/US2019/042711 patent/WO2020018975A1/en unknown
- 2019-07-19 JP JP2021502987A patent/JP7320595B2/en active Active
- 2019-07-19 KR KR1020217002210A patent/KR20210034596A/en unknown
- 2019-07-19 CN CN201980048375.6A patent/CN112513048A/en active Pending
- 2019-07-19 BR BR112021001044-0A patent/BR112021001044A2/en unknown
- 2019-07-19 MX MX2021000780A patent/MX2021000780A/en unknown
- 2019-07-19 MA MA053172A patent/MA53172A/en unknown
- 2019-07-19 CA CA3105521A patent/CA3105521A1/en active Pending
- 2019-07-22 TW TW108125886A patent/TWI825134B/en active
- 2019-07-22 AR ARP190102055A patent/AR115822A1/en unknown
-
2020
- 2020-12-07 IL IL279256A patent/IL279256A/en unknown
-
2021
- 2021-01-15 US US17/150,349 patent/US20210253596A1/en active Pending
- 2021-01-19 CL CL2021000153A patent/CL2021000153A1/en unknown
- 2021-01-19 PH PH12021500005A patent/PH12021500005A1/en unknown
- 2021-02-10 CO CONC2021/0001530A patent/CO2021001530A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112513048A (en) | 2021-03-16 |
| CA3105521A1 (en) | 2020-01-23 |
| AR115822A1 (en) | 2021-03-03 |
| TWI825134B (en) | 2023-12-11 |
| PE20211811A1 (en) | 2021-09-14 |
| KR20210034596A (en) | 2021-03-30 |
| WO2020018975A1 (en) | 2020-01-23 |
| US20210253596A1 (en) | 2021-08-19 |
| CO2021001530A2 (en) | 2021-03-08 |
| MA53172A (en) | 2021-05-26 |
| JP7320595B2 (en) | 2023-08-03 |
| TW202016078A (en) | 2020-05-01 |
| AU2019306658A1 (en) | 2021-01-07 |
| CL2021000153A1 (en) | 2021-07-09 |
| PH12021500005A1 (en) | 2021-09-13 |
| EP3823974A1 (en) | 2021-05-26 |
| BR112021001044A2 (en) | 2021-04-13 |
| MX2021000780A (en) | 2021-03-31 |
| CR20210022A (en) | 2021-02-18 |
| IL279256A (en) | 2021-01-31 |
| JP2021532101A (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279256A (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | |
| IL267961A (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| IL280139A (en) | Sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| IL282535A (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| EP3268367B8 (en) | Carboxamide inhibitors of irak4 activity | |
| EP3268006A4 (en) | Pyrrolotriazine inhibitors of irak4 activity | |
| EP3267996A4 (en) | Pyrazolopyrimidine inhibitors of irak4 activity | |
| EP3268004A4 (en) | Pyrrolopyridazine inhibitors of irak4 activity | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| IL281939A (en) | Inhibitors of vap-1 | |
| EP3200787A4 (en) | Inhibitors of irak4 activity | |
| EP3200788A4 (en) | Inhibitors of irak4 activity | |
| EP3200789A4 (en) | Inhibitors of irak4 activity | |
| EP3801503A4 (en) | Inhibitors of sarm1 | |
| EP3906029A4 (en) | Inhibitors of menin-mll interaction | |
| IL290929A (en) | Substituted cyanopyrrolidines with activity as usp30 inhibitors | |
| DK3681885T3 (en) | TETRAHYDRO-IMIDAZO-QUINOLINE COMPOUNDS AS CBP/P300 INHIBITORS | |
| IL281815A (en) | Inhibitors of vap-1 | |
| ZA202106766B (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| EP3261631A4 (en) | Inhibition of olig2 activity | |
| EP3801499A4 (en) | Inhibitors of sarm1 | |
| IL276312A (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| EP3801500A4 (en) | Inhibitors of sarm1 | |
| EP3294721A4 (en) | 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors | |
| EP3801525A4 (en) | Inhibitors of prolyl-trna-synthetase |